Does Rallies show Form 4 insider transactions for INCY?

Yes. Rallies tracks INCY insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is INCY research on Rallies investment advice?

No. Rallies provides research, data, and educational context for INCY. It does not provide personalized investment advice.

INCY (Incyte) Stock Analysis - Insider Trades

Incyte (INCY) is a publicly traded Healthcare sector company. As of May 20, 2026, INCY trades at $97.40 with a market cap of $19.02B and a P/E ratio of 36.15. INCY moved +1.56% today. Year to date, INCY is -4.63%; over the trailing twelve months it is +48.67%. Its 52-week range spans $53.56 to $112.29. Analyst consensus is buy with an average price target of $109.13. Rallies surfaces INCY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading INCY stock inside the company?

Recent INCY insider activity includes CAGNONI PABLO J sold 18.67K, CAGNONI PABLO J sold 18.67K, CAGNONI PABLO J sold 18.67K, Issa Mohamed Khairie sold 10.86K, and Stein Steven H sold 15.63K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

INCY Key Metrics

Key financial metrics for INCY
Metric	Value
Price	$97.40
Market Cap	$19.02B
P/E Ratio	36.15
EPS	$2.67
Dividend Yield	0.00%
52-Week High	$112.29
52-Week Low	$53.56
Volume	704.20K
Avg Volume	0
Revenue (TTM)	$3.70B
Net Income	$597.60M
Gross Margin	93.10%

Recent INCY Insider Trades

CAGNONI PABLO J sold 18.67K (~$1.80M) on Apr 17, 2026.
CAGNONI PABLO J sold 18.67K (~$1.76M) on Mar 17, 2026.
CAGNONI PABLO J sold 18.67K (~$1.88M) on Feb 19, 2026.
Issa Mohamed Khairie sold 10.86K (~$1.18M) on Jan 7, 2026.
Stein Steven H sold 15.63K (~$1.59M) on Jan 5, 2026.

Latest INCY News

Incyte to Present 20+ Abstracts Highlighting Hematology Pipeline at EHA 2026 Congress — May 12, 2026
Incyte drops on 2026 revenue guidance shortfall despite Q1 earnings beat — Apr 30, 2026
Incyte jumps after Q1 revenue surge, upbeat pipeline and guidance reaffirmation — Apr 29, 2026
Incyte Gains FDA Acceptance for HS Therapy, Eyes 1H27 Vitiligo Filing — Apr 29, 2026
Incyte slides after Q1 beat as 2026 revenue guidance misses estimates — Apr 28, 2026

INCY Analyst Consensus

17 analysts cover INCY: 0 strong buy, 8 buy, 8 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $109.13.

Common questions about INCY

Who is trading INCY stock inside the company?: Recent INCY insider activity includes CAGNONI PABLO J sold 18.67K, CAGNONI PABLO J sold 18.67K, CAGNONI PABLO J sold 18.67K, Issa Mohamed Khairie sold 10.86K, and Stein Steven H sold 15.63K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for INCY?: Yes. Rallies tracks INCY insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is INCY research on Rallies investment advice?: No. Rallies provides research, data, and educational context for INCY. It does not provide personalized investment advice.